<code id='3E4F25D9E4'></code><style id='3E4F25D9E4'></style>
    • <acronym id='3E4F25D9E4'></acronym>
      <center id='3E4F25D9E4'><center id='3E4F25D9E4'><tfoot id='3E4F25D9E4'></tfoot></center><abbr id='3E4F25D9E4'><dir id='3E4F25D9E4'><tfoot id='3E4F25D9E4'></tfoot><noframes id='3E4F25D9E4'>

    • <optgroup id='3E4F25D9E4'><strike id='3E4F25D9E4'><sup id='3E4F25D9E4'></sup></strike><code id='3E4F25D9E4'></code></optgroup>
        1. <b id='3E4F25D9E4'><label id='3E4F25D9E4'><select id='3E4F25D9E4'><dt id='3E4F25D9E4'><span id='3E4F25D9E4'></span></dt></select></label></b><u id='3E4F25D9E4'></u>
          <i id='3E4F25D9E4'><strike id='3E4F25D9E4'><tt id='3E4F25D9E4'><pre id='3E4F25D9E4'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:5
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In